References
- Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148–55.
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098–104.
- Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099–104.
- Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific Detection of Tuberculosis Infection an Interferon-gamma Based Assay using New Antigens. Accepted for publication in Am J Respir Crit Care Med. In press 2004 Apr 1.
- Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P.Comparison of a New Specific Blood Test and the Skin Test in Tuberculosis Contacts. Am J Respir Crit Care Med. In press 2004 Apr 15.
- Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, Eguale T, et al. Immune responses to the Mycobacterium tuberculosis- specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002 Feb; 40(2): 704–6.